



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Examiner: McKelvey, Terry Alan
	)	
Kevin P. BAKER, et al.	)	Art Unit: 1636
	)	
Application Serial No. 10/006,116	)	Confirmation No: 8110
	)	
Filed: December 6, 2001	)	Attorney's Docket No. 39780-2830 P1C15
	)	
For: <b>SECRETED AND</b>	)	<b>Customer No. 35489</b>
<b>TRANSMEMBRANE</b>	)	
<b>POLYPEPTIDES AND NUCLEIC</b>	)	
<b>ACIDS ENCODING THE SAME</b>	)	

EXPRESS MAIL LABEL NO.: EL 976 545 016 US  
DATE MAILED: JULY 5, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

**MAIL STOP AMENDMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --

☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☒ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39780-2830 P1C15).**


Respectfully submitted,

Dated: July 5, 2005

By: Barrie D. Greene  
Barrie D. Greene (Reg. No. 46,740)

**HELLER EHRMAN LLP**  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 2131072 v1  
(39780.2830)



<b>Form PTO-1446</b>				<b>Attorney's Docket No.</b> 39780-2830 PIC15		<b>Application Serial No.</b> 10/006,116	
<b>INFORMATION DISCLOSURE STATEMENT</b>				<b>Applicant(s)</b> Kevin P. BAKER, et al.			
<i>(use several sheets if necessary)</i>				<b>Filing Date:</b> December 6, 2001		<b>Group Art Unit:</b> 1636	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>	<b>Ref. No.</b>	<b>Date</b>	<b>Document No.</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date (if appropriate)</b>
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>	<b>Ref. No.</b>	<b>Date</b>	<b>Document No.</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>
							YES NO
<b>OTHER DOCUMENTS</b> <i>(including author, title, date, pertinent pages, etc.)</i>							
<b>Examiner Initials</b>	<b>Ref. No.</b>	<b>Title</b>					
	1.	Goldwasser, Itzhak, et al., "L-Glutamic Acid $\gamma$ -Monohydroxamate", The Journal of Biomedical Chemistry, Vol. 274, No. 37, pp 26617-26624, September 10, 1999.					
	2.	Hanna, J.S., et al., "HER-2/neu Breat Cancer Predictive Testing", Oathology Associates Medical Laboratores - (1999).					
	3.	Hyman, E., et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer <sup>1,2</sup> ", <i>Cancer Research</i> - 62:6240-6245 (2002).					
	4.	Janeway, Charles A., et al., "Immuno Biology: The Immune System in Health and Disease, Chapter 3: Antigen Recognition by B-cell and T-cell Receptors", 5th Edition, Garland Publishing, New York, NY, pp 102-103, 2001.					
	5.	Mueller, Wendy M., et al., "Evidence That Glucose Metabolism Regulates Leptin Secretion from Cultured Rat Adipocytes", <i>Endocrinology</i> , Vol. 139, No. 2, pp 551-558 (1998).					
	6.	Mueller, Wendy M., et al., "Effects of Metformin and Vanadium on Leptin Secretion from Cultured Rat Adipocytes", <i>Obesity Research</i> , Vol. 8, No. 7, pp 530-539, October 2000.					
	7.	Orntoft, T.F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-Invasive and Invasive Human Transitional Cell Carcinomas", <i>Molecular &amp; Cellular Proteomics</i> - 1:37-45 (2002).					
	8.	Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors", <i>PNAS</i> - 99(20):12963-12968 (2002).					
	9.	Sandouk, Tagrid, et al., "The Antidiabetic Agent Pioglitazone Increases Expression of Glucose Transporters in 3T3-F442A Cells by Increasing Messenger Ribonucleic Acid Transcript Stability", <i>Endocrinology</i> , Vol. 133, No. 1, pp 352-359 (1993).					
	10.	Tafari, Sherrie R., "Troglitazone Enhances Differentiation, Basal Glucose Uptake, and Glut 1 Protein Levels in 3T3-L1 Adipocytes", <i>Endocrinology</i> , Vol. 137, No. 11, pp 4706-4712 (1996).					
	11.	Winter, Greg, et al., "Making Antibodies by Phage Display", <i>Annu. Rev. Immunol.</i> , Chpt 12, pp 433-55 (1994).					

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).